Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 34

1.

A Review on the Clinical Utility of PSA in Cancer Prostate.

Adhyam M, Gupta AK.

Indian J Surg Oncol. 2012 Jun;3(2):120-9. doi: 10.1007/s13193-012-0142-6. Epub 2012 Mar 3.

PMID:
23730101
[PubMed]
Free PMC Article
2.

Counterpoint: Prostate-specific antigen velocity is not of value for early detection of cancer.

Vickers AJ.

J Natl Compr Canc Netw. 2013 Mar 1;11(3):286-90.

PMID:
23486455
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer.

Xu J, Escamilla J, Mok S, David J, Priceman S, West B, Bollag G, McBride W, Wu L.

Cancer Res. 2013 May 1;73(9):2782-94. doi: 10.1158/0008-5472.CAN-12-3981. Epub 2013 Feb 15.

PMID:
23418320
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Updated results of magnetic resonance imaging guided partial prostate brachytherapy for favorable risk prostate cancer: implications for focal therapy.

Nguyen PL, Chen MH, Zhang Y, Tempany CM, Cormack RA, Beard CJ, Hurwitz MD, Suh WW, D'Amico AV.

J Urol. 2012 Oct;188(4):1151-6. doi: 10.1016/j.juro.2012.06.010. Epub 2012 Aug 15.

PMID:
22901567
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

PSA Velocity and Doubling Time in Diagnosis and Prognosis of Prostate Cancer.

Vickers AJ, Brewster SF.

Br J Med Surg Urol. 2012 Jul 1;5(4):162-168.

PMID:
22712027
[PubMed]
Free PMC Article
6.

The relationship of the intensity of posttreatment prostate-specific antigen surveillance and prostate cancer outcomes: results from a population-based cohort.

Nabhan M, Kim SP, Shah ND, Bagniewski SM, Shi Q, Karnes RJ, Weight CJ, Davis BJ, Kohli M, Tilburt JC.

Mayo Clin Proc. 2012 Jun;87(6):540-7. doi: 10.1016/j.mayocp.2012.01.017.

PMID:
22677074
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Radiation treatment for patients with intermediate-risk prostate cancer.

Greene DE, Mayadev JS, Valicenti RK.

Ther Adv Urol. 2012 Jun;4(3):113-24. doi: 10.1177/1756287212442977.

PMID:
22654963
[PubMed]
Free PMC Article
8.
9.

Differentiation of lethal and non lethal prostate cancer: PSA and PSA isoforms and kinetics.

Carter HB.

Asian J Androl. 2012 May;14(3):355-60. doi: 10.1038/aja.2011.141. Epub 2012 Feb 20. Review.

PMID:
22343493
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer.

Loeb S, Metter EJ, Kan D, Roehl KA, Catalona WJ.

BJU Int. 2012 Feb;109(4):508-13; discussion 513-4. doi: 10.1111/j.1464-410X.2011.10900.x. Epub 2012 Feb 1.

PMID:
22296334
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Prognostic determinants in prostate cancer.

Martin NE, Mucci LA, Loda M, Depinho RA.

Cancer J. 2011 Nov-Dec;17(6):429-37. doi: 10.1097/PPO.0b013e31823b042c. Review.

PMID:
22157287
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

An update on the changing indications for androgen deprivation therapy for prostate cancer.

Myklak K, Wilson S.

Prostate Cancer. 2011;2011:419174. doi: 10.1155/2011/419174. Epub 2011 Feb 7.

PMID:
22110986
[PubMed]
Free PMC Article
13.

Tumor markers in prostate cancer I: blood-based markers.

Shariat SF, Semjonow A, Lilja H, Savage C, Vickers AJ, Bjartell A.

Acta Oncol. 2011 Jun;50 Suppl 1:61-75. doi: 10.3109/0284186X.2010.542174. Review.

PMID:
21604943
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

PSA velocity may not be of value in prostate cancer detection.

Johnston D, Terris MK.

Asian J Androl. 2011 Jul;13(4):616-7. doi: 10.1038/aja.2011.43. Epub 2011 May 23. No abstract available.

PMID:
21602830
[PubMed]
Free PMC Article
15.

Should prostate-specific antigen velocity be abandoned?

Loeb S, Carter HB.

Asian J Androl. 2011 May;13(3):359-60. doi: 10.1038/aja.2011.34. Epub 2011 Apr 18. No abstract available.

PMID:
21499277
[PubMed]
Free PMC Article
16.

Development of a real-time clinical decision support system upon the Web MVC-based architecture for prostate cancer treatment.

Lin HC, Wu HC, Chang CH, Li TC, Liang WM, Wang JY.

BMC Med Inform Decis Mak. 2011 Mar 8;11:16. doi: 10.1186/1472-6947-11-16.

PMID:
21385459
[PubMed - indexed for MEDLINE]
Free PMC Article
17.
18.

Diffusion-weighted magnetic resonance imaging for monitoring prostate cancer progression in patients managed by active surveillance.

Morgan VA, Riches SF, Thomas K, Vanas N, Parker C, Giles S, Desouza NM.

Br J Radiol. 2011 Jan;84(997):31-7. doi: 10.1259/bjr/14556365.

PMID:
21172965
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively.

O'Brien MF, Cronin AM, Fearn PA, Savage CJ, Smith B, Stasi J, Scardino PT, Fisher G, Cuzick J, Møller H, Oliver RT, Berney DM, Foster CS, Eastham JA, Vickers AJ, Lilja H; Trans-Atlantic Prostate Group.

Int J Cancer. 2011 May 15;128(10):2373-81. doi: 10.1002/ijc.25570.

PMID:
20658531
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy.

Vickers AJ, Wolters T, Savage CJ, Cronin AM, O'Brien MF, Roobol MJ, Aus G, Scardino PT, Hugosson J, Schröder FH, Lilja H.

J Urol. 2010 Sep;184(3):907-12. doi: 10.1016/j.juro.2010.05.029.

PMID:
20643434
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk